Gilmore O'Neill, M.B., M.M.Sc

2020

In 2020, Gilmore O'Neill, M.B., M.M.Sc earned a total compensation of $3.8M as Executive Vice President, Chief Scientific Officer at Sarepta Therapeutics, a 27% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$293,164
Option Awards$2,131,159
Salary$583,277
Stock Awards$766,949
Other$15,500
Total$3,790,049

MMSc received $2.1M in option awards, accounting for 56% of the total pay in 2020.

MMSc also received $293.2K in non-equity incentive plan, $583.3K in salary, $766.9K in stock awards and $15.5K in other compensation.

Rankings

In 2020, Gilmore O'Neill, M.B., M.M.Sc's compensation ranked 3,032nd out of 13,090 executives tracked by ExecPay. In other words, MMSc earned more than 76.8% of executives.

ClassificationRankingPercentile
All
3,032
out of 13,090
77th
Division
Manufacturing
1,183
out of 5,618
79th
Major group
Chemicals And Allied Products
448
out of 2,251
80th
Industry group
Drugs
388
out of 1,951
80th
Industry
Pharmaceutical Preparations
289
out of 1,456
80th

Pay ratio

Gilmore O'Neill, M.B., M.M.Sc's Pay$3,790,049
Median Employee's Pay$275,247
Pay Ratio

14

to 1

In 2020, the annual total compensation of Gilmore O'Neill, M.B., M.M.Sc was $3,790,049.

The annual total compensation of the median employee at Sarepta Therapeutics was $275,247.

The ratio of Gilmore O'Neill, M.B., M.M.Sc's pay to the pay of median employee was therefore 14 to one.

Source: SEC filing on April 25, 2022.

MMSc's colleagues

We found seven more compensation records of executives who worked with Gilmore O'Neill, M.B., M.M.Sc at Sarepta Therapeutics in 2020.

2020

Louise Rodino-Klapac

Sarepta Therapeutics

Chief Scientific Officer

2020

David Howton

Sarepta Therapeutics

General Counsel

2020

Ian Estepan

Sarepta Therapeutics

Chief Financial Officer

2020

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2020

Douglas Ingram

Sarepta Therapeutics

Chief Executive Officer

2020

Joseph Bratica

Sarepta Therapeutics

Vice President, Corporate Controller

2020

William Ciambrone

Sarepta Therapeutics

Executive Vice President, Technical Operations

News

In-depth

You may also like